Stockscreener 앱 받기
0.709
0.28%
-0.002
시간 외 거래:
.71
0.001
+0.14%
전일 마감가:
$0.711
열려 있는:
$0.7248
하루 거래량:
11,003
Relative Volume:
0.24
시가총액:
$5.79M
수익:
$4.83M
순이익/손실:
$-2.99M
주가수익비율:
-1.4759
EPS:
-0.4804
순현금흐름:
$-2.83M
1주 성능:
-12.47%
1개월 성능:
-1.80%
6개월 성능:
-62.68%
1년 성능:
-60.45%
1일 변동 폭
$0.709
$0.7248
1주일 범위
$0.709
$0.8649
52주 변동 폭
$0.6765
$2.39
이뮤론 Stock (IMRN) Company Profile
Compare IMRN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
0.709 | 5.81M | 4.83M | -2.99M | -2.83M | -0.4804 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
이뮤론 주식(IMRN)의 최신 뉴스
IMRN Earnings History & Surprises | EPS & Revenue Results | IMMURON LTD-SPON ADR (NASDAQ:IMRN) - ChartMill
Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Sahm
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Sarasota Herald-Tribune
$3.90 target: analyst backs Immuron after sales rise and cash boost - Stock Titan
Immuron Reports HY26 Results and Strategic Reset - GlobeNewswire Inc.
Immuron Reports HY26 Results and Strategic Reset - ChartMill
Immuron (NASDAQ: IMRN) gains A$1.12M non-dilutive R&D refund - Stock Titan
Immuron (NASDAQ: IMRN) shareholders back ratification of prior share issues - Stock Titan
Immuron Limited (IMRN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - progress-index.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron Reports Continued Sales Growth - Finviz
Does Immuron Limited (Common Stock) (ANWA) stock trade below intrinsic valueJuly 2025 Spike Watch & Smart Investment Allocation Insights - DonanımHaber
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Limited Announces Quotation of New Securities on ASX - The Globe and Mail
Immuron stock tumbles after trial fails to meet primary endpoint By Investing.com - Investing.com Australia
Orla Mining Ltd (ORLA) Performance and Fundamentals Dashboard tells a completely different story - setenews.com
Immuron stock tumbles after trial fails to meet primary endpoint - Investing.com India
Immuron Limited announces quotation of new securities on ASX - MSN
Check Out IHS Holding Ltd (IHS)’s Trade Data Rather Than the Analysts’ Views - setenews.com
You might want to take a look at Embecta Corp (EMBC) now - setenews.com
Why UiPath Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
ANWA Forecast — Price Target — Prediction for 2026 - TradingView — Track All Markets
Immuron Limited (IMRN) Plunges Amidst Management Uncertainty and Bearish Market Sentiment - FinancialContent
Why Immuron Limited (ANW) stock gets analyst attentionJuly 2025 Recap & Safe Capital Growth Stock Tips - newser.com
IMRN Stock Price and Chart — NASDAQ:IMRN - TradingView
How Immuron Limited Depositary Receipt stock benefits from global expansion2025 Macro Impact & AI Driven Price Forecasts - Fundação Cultural do Pará
Immuron Reports Strong FY2025 Results and Outlines FY2026 Plans - TipRanks
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Holdings of Immuron Limited ADR (IMRN) are aligned with the stars - Setenews
Immuron Limited Receives FDA Approval for IMM-529 Investigational New Drug Application for Clostridioides difficile Infection Treatment - Quiver Quantitative
Immuron IMM-529 IND approved by FDA - GlobeNewswire
Immuron CEO to Present at AusBiotech Invest 2025 Conference - MSN
Immuron Announces Clinical Trial Update - Sahm
Immuron Ltd (IMC:ASX) - smallcaps.com.au
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
이뮤론 (IMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):